期刊文献+

AFP-L3阳性肝细胞癌患者肿瘤分期和外周血淋巴细胞亚群的研究 被引量:3

Tumor stages and peripheral blood lymphocyte subsets in patients with AFP-L3-positive hepatocellular carcinoma
下载PDF
导出
摘要 目的:分析小扁豆凝素结合型甲胎蛋白(AFP-L3)阳性的肝细胞癌患者肿瘤分期及外周血淋巴细胞的改变,探讨AFP-L3水平与肿瘤分期及免疫状态的关系。方法:采集60例肝细胞癌患者外周血,检测AFP及AFP-L3含量。根据外周血AFP-L3比例将60例原发性肝细胞癌患者分为2组:AFP-L3(+)组和AFP-L3(-)组。流式细胞术检测外周血中各淋巴细胞亚群(NK、CD4+、CD8+、CD4/CD8、Treg)的比例。结果:AFP-L3(+)组患者UICC分期Ⅲ+Ⅳ期为29例,AFP-L3(-)组为7例;AFP-L3(+)组患者BCLC分期C+D期为20例,AFP-L3(-)组为3例。AFP-L3(+)组患者发生血管侵犯为17例,远高于AFP-L3(-)组(1例)。AFP-L3(+)组患者外周血中NK细胞比例及CD4/CD8比值下降,CD8+T和Treg细胞显著比例上升。结论:外周血AFP-L3阳性的肝癌患者容易发生血管侵犯,且分期较差,可能与淋巴细胞亚群发生变化、免疫系统受到抑制有关。 AIM: To analyze the variations of tumor stages and peripheral blood lymphocyte subsets in Lens culinaris agglutinin-reactive alpha-fetoprotein(AFP-L3)-positive hepatocellular carcinoma(HCC) and to explore the relationship between tumor stage,immune state and AFP-L3.METHODS: Peripheral blood of sixty HCC patients was collected.The concentrations of AFP and AFP-L3 were detected.The patients were divided into 2 groups according to the expression of AFP-L3: AFP-L3(+) group and AFP-L3(-) group.The variations of T-lymphocyte subsets,natural killer T-cells(NK,CD3+ CD16+CD56+),CD4+ T-cells(CD3+ CD4+),CD8+ T-cells(CD3+ CD8+),CD4/CD8 ratio and regulatory T-cells(Treg,CD4+ CD25+ Foxp3+),were analyzed by flow cytometry.RESULTS: According to the International Union against Cancer(UICC) staging system,29 patients in AFP-L3(+) group were in stage III and IV,while only 7 patients in AFP-L3(-) group were in stage III and IV.According to the Barcelona Clinic Liver Cancer(BCLC) staging system,20 patients in AFP-L3(+) group were in stage C and D,while only 3 patients in AFP-L3(-) group were in stage C and D.Seventeen patients in AFP-L3(+) group suffered vascular invasion,significantly more than those in AFP-L3(-) group.The percentage of NK cells and CD4/CD8 ratio decreased in AFP-L3(+) group,while the percentages of CD8+ and Treg cells significantly increased.CONCLUSION: The AFP-L3(+) patients have liability to vascular invasion and worse tumor stages,which may relate to variations of lymphocyte subsets and suppression of the immune system.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2011年第5期843-847,共5页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81071892) 广东省科技计划资助项目(No.2008B080703031 No.2010B031500026)
关键词 肝细胞癌 小扁豆凝集素结合型甲胎蛋白 肿瘤分期 淋巴细胞亚群 Hepatocellular carcinoma Lens culinaris agglutinin-reactive alpha-fetoprotein Tumor staging Lymphocyte subsets
  • 相关文献

参考文献17

  • 1Bruix J,Sherman M.Management of hepatocellular carcinoma[J].Hepatology,2005,42(5):1208-1236.
  • 2Taketa K,Endo Y,Sekiya C,et al.A collaborative study for the evaluation of lectin-reactive α-fetoproteins in early detection of hepatocellular carcinoma[J].Cancer Res,1993,53(22):5419-5423.
  • 3Oka H,Saito A,Ito K,et al.Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of AFP-L3[J].J Gastroenterol Hepatol,2001,16(12):1378-1383.
  • 4Okuda H,Nakanishi T,Takatsu K,et al.Clinicopathologic features of patients with hepatocellular carcinoma seropositive for α-fetoprotein-L3 and seronegative for des-γ-carboxy prothrombin in comparison with those seropositive for des-γ-carboxy prothrombin alone[J].J Gastroenterol Hepatol,2002,17(7):772-778.
  • 5Hagiwara S,Kudo M,Kawasaki T,et al.Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma[J].J Gastroenterol,2006,41(12):1214-1219.
  • 6Carr BI,Kanke F,Wise M,et al.Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States[J].Dig Dis Sci,2007,52(3):776-782.
  • 7Song BC,Suh DJ,Yang SH,et al.Lens culinaris agglutinin-reactive alpha-fetoprotein as a prognostic marker in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization[J].J Clin Gastroenterol,2002,35(5):398-402.
  • 8Toyoda H,Kumada T,Kaneoka YJ,et al.Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC[J].J Hepatol,2008,49(2):223-232.
  • 9汪礼坤,匡铭,彭宝岗,何强,李绍强,华赟鹏,陈斌,王晔.Tregs调节小鼠肝癌局部引流淋巴结内免疫效应细胞的功能[J].中国病理生理杂志,2010,26(5):922-927. 被引量:4
  • 10Attallah AM,Tabll AA,El-Sadany M,et al.Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma[J].Clin Exp Med,2003,3(3):181-185.

二级参考文献20

  • 1Bruix J,Llovet JM.Major achievements in hepatocellular carcinoma[J].Lancet,2009,373(9664):614-616.
  • 2Butterfield LH.Recent advances in immunotherapy for hepatocellular cancer[J].Swiss Med Wkly,2007,137(5-6):83-90.
  • 3Wada Y,Nakashima O,Kutami R,et al.Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration[J].Hepatology,1998,27(2):407-414.
  • 4Unitt E,Rushbrook SM,Marshall A,et al.Compromised lymphocytes infiltrate hepatocellular carcinoma:the role of T-regulatory cells[J].Hepatology,2005,41(4):722-730.
  • 5Sakaguchi S.Regulatory T cells:key controllers of immunologic self-tolerance[J].Cell,2000,101(5):455-458.
  • 6Zou W.Regulatory T cells,tumor immunity and immunotherapy[J].Nat Rev Immunol,2006,6(4):295-307.
  • 7Curiel TJ.Regulatory T cells and treatment of cancer[J].Curr Opin Immunol,2008,20(2):241-246.
  • 8Munn DH,Mellor AL.The tumor-draining lymph node as an immune-privileged site[J].Immunol Rev,2006,213:146-158.
  • 9Currier JR,Kuta EG,Turk E,et al.A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays[J].J Immunol Methods,2002,260(1-2):157-172.
  • 10Fontenot JD,Gavin MA,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+ regulatory T cells[J].Nat Immunol,2003,4(4):330-336.

共引文献3

同被引文献37

  • 1易伟,胡志前,龚振斌.Ki-67抗原和p53蛋白在胃癌中的表达及其临床意义[J].中国普通外科杂志,2006,15(9):664-667. 被引量:16
  • 2Ding R, Han S, Lu Y, et al. Overexpressed Id-1 is associated with patient prognosis and HBx expression in hepatitis B virus-related hepa/ocellular carcinoma[J]. Cancer Biol Ther, 2010, 10(3):299- 307.
  • 3Wong YC, Wang X, Ling MT, Id-1 expression and cell survival[J]. Apoptosis, 2004, 9(3):279-289.
  • 4Yokota Y, Mori S. Role of Id family proteins in growth control[J]. J Cell Physiol, 2002, 190(1):21-28.
  • 5Dong Z, Liu S, Zhou C, et al. Overexpression of ld-1 is associated with tumor angiogenesis and poor clinical outcome in oral squamous cell carcinoma[J]. Oral Oncol, 2010, 46(3):154-157.
  • 6Maw MK, Fujimoto J, Tamaya T. Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers[J]. BMC Cancer, 2009, 9:430.
  • 7Maw MK, Fujimoto J, Tamaya T. Expression of the inhibitor of DNA-binding (ID)-l protein as an angiogenic mediator in turnout advancement of uterine cervical cancers[J]. Br J Cancer, 2008, 99(10):1557-1563.
  • 8Cheung HW, Ling MT, Tsao SW, et al. Id-l-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells[J]. Carcinogenesis, 2004, 25(6):881-887.
  • 9Zhang XF, Lai EC, Kang XY, et al. Lens culinaris agglutinin-reaetive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection [J]. Ann Surg Oncol,2011,18(8) :2218-2223.
  • 10Wu F, Yang LY, Li YF, et al. Novel role for epidermal growth factor- like domain 7 in metastasis of human hepatocellular carcinoma [ J ]. Hepatology ,2009,50 ( 6 ) :1839-1850.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部